<DOC>
	<DOCNO>NCT00002249</DOCNO>
	<brief_summary>To determine safety pharmacokinetics L-ofloxacin ( RWJ 25213 ) patient HIV infection .</brief_summary>
	<brief_title>A Double-Blind Study Evaluate Safety Pharmacokinetics L-Ofloxacin ( RWJ 25213 ) Subjects With HIV Infection</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Levofloxacin</mesh_term>
	<mesh_term>Ofloxacin</mesh_term>
	<criteria>Inclusion Criteria Patients must follow : HIV infection . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Active opportunistic infection neoplasm . High likelihood death study . Significant ophthalmologic , renal , hepatic , cardiovascular , hematologic , neurologic , psychiatric , respiratory , metabolic disease . Donation &gt; 1 unit blood acute loss blood within one month study entry . Patients follow prior condition exclude : History opportunistic infection . Previous allergic reaction ciprofloxacin , norfloxacin , quinolone . Prior Medication : Excluded : Use investigational agent within 7 day entry study . Use medication within 3 day prior entry ( 7 day AZT ) . Alcohol drug abuse .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 1991</verification_date>
	<keyword>Anti-Infective Agents , Quinolone</keyword>
	<keyword>Ofloxacin</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
</DOC>